



Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
(CIN:L24232GJ1996PLC029894)



Date: 04 November 2022

Ref No.: TCPCL/SEC/2022-23/00071

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001
Scrip Code: 543321

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla, Complex Bandra(E),
Mumbai-400 051
Scrip Symbol: TATVA

Subject: Press Release on the financial results

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on financial results of the Company for the quarter and half year ended 30 September 2022.

The above information shall be made available on the website of the Company at www.tatvachintan.com.

This is for your information and records.

Thanking You,

Your Faithfully,
For Tatva Chintan Pharma Chem Limited

Ishwar Ramanbhai Nayi
Digitally signed by
Ishwar Ramanbhai
Nayi
Date: 2022.11.04
16:46:51 +05'30'

Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444

Encl: As above



Tatva Chintan Pharma Chem Limited

Financial Press Release: Q2 & H1FY23

Vadodara, 4th November 2022: Tatva Chintan Pharma Chem Limited (TCPCL) BSE: 543321, NSE: TATVA, ISIN: INEOGK401011, an integrated niche speciality chemical company, has announced its financial results for the quarter and half year ended 30 September 2022, as approved by the Board of Directors.

Consolidated Results at Glance:

Y-O-Y – Q2FY23 COMPARED WITH Q2FY22

- **Revenue from Operations** for the quarter was ₹ 901 million, declined by 27%
- **EBITDA** for the quarter was ₹ 112 million, declined by 68%
- **EBIDTA Margin** for the quarter was at 12%
- **Net Profit** for the quarter was ₹ 71 million, declined by 78%
- **Net Profit Margin** for the quarter was at 8%
- **Basic and Diluted EPS** for the quarter was ₹ 3.21 per share

Y-O-Y – H1FY23 COMPARED WITH H1FY22

- **Revenue from Operations** for the half year was ₹ 1,785 million, declined by 23%
- **EBITDA** for the half year was ₹ 264 million, declined by 57%
- **EBIDTA Margin** for the half year was at 15%
- **Net Profit** for the half year was ₹ 169 million, declined by 70%
- **Net Profit Margin** for the half year was at 9%
- **Basic and Diluted EPS** for the half year was ₹ 7.63 per share

Update on the Product Categories:

- **Phase Transfer Catalysts (PTCs)** comprised 41% of the revenue during H1FY23, reporting a revenue growth of nearly 69% YoY basis. These products are used as catalysts in manufacturing Pharmaceutical APIs, Flavors & Fragrances, Agrochemicals, etc.
- **Structure Directing Agents (SDAs)** comprised 9% of the revenue during H1FY23, reporting a decline of 88% YoY basis. SDAs are the key building blocks for manufacturing high precision zeolite which finds application in Automotive emission control, Petrochemicals, Continuous flow chemistry, etc.
- **Electrolyte Salts (ES)** comprised 6% of the revenue and in absolute numbers revenue grew by 846% y-o-y. ES are used in super capacitor batteries which find application in automobile, electronics and energy storage devices.
- **Pharma Agro Intermediates and Specialty Chemicals (PASC)** product category comprised 43% of the revenue, saw a YoY growth of 45%. PASC finds application in Pharmaceutical APIs, Agro Actives, paints and coatings, Li battery, detergents, personal care products, etc.

Commenting on Q2FY23 Results, Mr. Chintan Shah, Managing Director, said, EBITDA during this quarter was ₹ 112 mn, a decline of 68% YOY and 27% QOQ. EBIDTA includes forex loss of ₹ 31.85 mn, so the actual operational EBIDTA during the quarter is ₹ 143.62 mn which translates into EBIDTA margin 16%. Forex loss is mainly because of MTM of forward contract due to depreciating rupee.

PAT was ₹ 71 mn, a decline of 78% YOY and 27% QOQ. Comparing on QOQ basis, the profitability has dropped due to increase in costs such as power & fuel, packing and employee cost during this quarter.

During this quarter, we have successfully completed various projects which will have a positive impact in our performance going forward. Just to name a few:



- Began re-using a large volume solvent at Dahej SEZ by deploying a latest technology. This will ensure competitiveness & cost saving in few products.
- Formulated plans to set-up this similar technology at our Ankleshwar plant.
- Successfully completed plant scale trials of flame retardants.
- Successfully supplied from pilot scale a new pharma intermediate to a new customer for validation. This product is expected to commercialize in 2024.
- Successfully completed pilot scale trial runs of a new product using continuous flow chemistry. This product is expected to be commercialized by 2024.
- Successfully completed lab scale development of a very important starting material for agro chemical intermediate.

The key factors we require to monitor is how the European energy crisis is rolling out over the next few months and about the Chinese and European demand revival for heavy duty commercial vehicles pans out.

The expansion is underway and progressing as per schedule at our Dahej SEZ plant. Out of our net IPO proceeds of ₹ 2,072.81 million, ₹ 506.36 mn have been utilized during Q2FY23 taking the total amount utilized to ₹ 1,339 mn as on 30 Sept. 2022.

About Tatva Chintan Pharma Chem Limited:

Tatva Chintan is an Integrated Specialty Chemical company, present across the value chain manufacturing Phase Transfer Catalyst, Structure Directing Agents, Electrolyte Salts and Pharma & Agrochemical Intermediates and Specialty Chemicals, established in the year 1996 by first generation entrepreneur engineers. It has two manufacturing facilities at Ankleshwar and Dahej SEZ, Gujarat with an existing combined installed reactor capacity of 294KL and 27 Assembly Lines, having Sophisticated R&D Unit recognized by DSIR at Vadodara, Gujarat. The company has a customer base spanning over 25 Countries including USA, UK, China, Germany, Japan and South Africa. Exports constitute 79% of the total revenue during FY22. The company is focused on serving customers across broad spectrum of chemical industries with applications in automotive, petrochemicals, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors & fragrances. For more information, please visit: www.tatvachintan.com

For Further details, please get in touch with:



Mr. Ashok Bothra

CFO, Tatva Chintan Pharma Chem Limited

Email: finance@tatvachintan.com



Ms. Krishna Patel, Mr. Rahul Thakur

Investor Relations, EY

krishna.patel2@in.ey.com,

rahul.thakur@in.ey.com.

Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward looking statements are subject to several known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward - looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Tatva Chintan Pharma Chem Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.